4.3 Article

Efficacy, tolerability and safety of a new medical device, Monurelle Biogel® vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age

Publisher

ELSEVIER
DOI: 10.1016/j.ejogrb.2016.05.005

Keywords

Vaginal dryness; Sexual function; Vaginal gel; Colostrum; Reproductive age

Funding

  1. Bayer-Schering Pharma
  2. Ely Lilly
  3. Gedeon-Richter
  4. HRA Pharma
  5. Merck Sharpe Dohme
  6. Novo Nordisk
  7. Pfizer Inc
  8. Shionogi Limited
  9. TEVA/Theramex
  10. Zambon SpA

Ask authors/readers for more resources

Objective: To prove the efficacy, tolerability and safety of Monurelle Biogel (R) (ZP-025) vaginal gel, which contains a purified, dialyzed, lyophilized bovine colostrum, in women of reproductive age suffering from vaginal dryness. Design: Randomized clinical trial (RCT) (Z7213M01). Setting: Five University Gynaecological Units. Patients: Ninety-five subjects were allocated at random to receive either ZP-025 (n = 48) for about 23 intermenstrual days (1 or 2 times/daily intra-vaginally) or no treatment (lubricants on demand were allowed). Main outcome measures: Change of Verbal Rating Scale (VRS) total and single score for vaginal symptoms, Vaginal Health Index (VHI) score, Female Sexual Function index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R) scores. Results: A total number of 85 subjects was evaluable for primary analyses. Symptoms (VRS) of vaginal discomfort improved significantly already after 11 days, as compared to the control arm (p < 0.0001). The mean VHI score was also significantly higher in ZP-025 group (p < 0.001) at the end of the study.The analysis of covariance with the baseline value as covariate carried out on the FSFI Total Score showed a statistically significant difference in favour of the ZP-025 arm (p < 0.032). A shift from presence to absence of sexual distress (<= 11 points) was more prominent in the ZP-025 arm [10 subjects (40%) in the ZP-025 arm (p < 0.0001) and 6 subjects (21.4%) in the control arm (p = 0.01)]. Women reported a compliance rate of 100% for one ZP-025 application/day. Local tolerability of ZP-025 was excellent or good in 82.9% of the subjects. Conclusions: The present multicentre RCT supports the use of Monurelle Biogel (R) in women of reproductive age reporting symptoms of vaginal dryness. A positive impact on vaginal health and sexual function was also evident. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available